Geneart AG increases production and turnover
The company founded in 1999 from the University of Regensburg, is one of the specialist leaders worldwide in the field of synthetic genes for research institutions and the pharmaceutical and bio-technology branches. The spectrum of output ranges from the manufacture of synthetic genes in accordance with DIN EN ISO 9001:2000, via the generation of gene libraries in combinatory biology to the production and development of DNA based substances. The team of over 100 employees in Regensburg and in the subsidiary GENEART Inc. in Toronto/Canada reached the profit zone for the first time in 2005. Since May 2006 GENEART has been listed on the German Stock Exchange. In the current business report for the year 2006 and to 1st quarter of 2007 the company has listed im-pressive figures. The turnover increased by over 70 % from 4.5 million EUR in 2005 to 7.8 million EUR in 2006. The company was also able to continue its growth rate in the 1st quarter of 2007 with a large contract from the US-American NIH (US-American Health Authority). With the monthly pro-duction of 1 million base pairs (1 Mbp), the company has broken through an important barrier. Ap-proaching the turn of the year 2007/2008 Geneart will be heading for the 2 million threshold. Fur-thermore the company is successfully contributing in innovative ways to the promotional research projects DECVAC (EU) and BioChancePlus (BMBF).
For more information see: